Loading...

Corcept Therapeutics

Nasdaq:CORT
Snowflake Description

Flawless balance sheet and good value.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CORT
Nasdaq
$1B
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The last earnings update was 68 days ago. More info.


Add to Portfolio Compare Print
CORT Share Price and Events
7 Day Returns
0%
NasdaqCM:CORT
-3%
US Pharmaceuticals
1.1%
US Market
1 Year Returns
-22.9%
NasdaqCM:CORT
5%
US Pharmaceuticals
4.7%
US Market
CORT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Corcept Therapeutics (CORT) 0% 3.5% -10.1% -22.9% 88.7% 339.3%
US Pharmaceuticals -3% -0.5% -0.1% 5% 2.6% 13.8%
US Market 1.1% 4.3% 2.9% 4.7% 37.7% 43.6%
1 Year Return vs Industry and Market
  • CORT underperformed the Pharmaceuticals industry which returned 5% over the past year.
  • CORT underperformed the Market in United States of America which returned 4.7% over the past year.
Price Volatility
CORT
Industry
5yr Volatility vs Market

Value

 Is Corcept Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Corcept Therapeutics to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Corcept Therapeutics.

NasdaqCM:CORT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 4 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.6%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqCM:CORT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.73
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.733 (1 + (1- 21%) (0.12%))
0.822
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.82
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.822 * 5.96%)
7.63%

Discounted Cash Flow Calculation for NasdaqCM:CORT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Corcept Therapeutics is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqCM:CORT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 7.63%)
2020 119.84 Est @ 14.82% 111.34
2021 133.25 Est @ 11.19% 115.03
2022 144.78 Est @ 8.65% 116.12
2023 154.74 Est @ 6.88% 115.31
2024 163.45 Est @ 5.63% 113.18
2025 171.23 Est @ 4.76% 110.16
2026 178.34 Est @ 4.15% 106.60
2027 184.99 Est @ 3.73% 102.74
2028 191.33 Est @ 3.43% 98.73
2029 197.49 Est @ 3.22% 94.68
Present value of next 10 years cash flows $1,083.90
NasdaqCM:CORT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $197.49 × (1 + 2.73%) ÷ (7.63% – 2.73%)
$4,141.68
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $4,141.68 ÷ (1 + 7.63%)10
$1,985.67
NasdaqCM:CORT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,083.90 + $1,985.67
$3,069.57
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $3,069.57 / 114.86
$26.72
NasdaqCM:CORT Discount to Share Price
Calculation Result
Value per share (USD) From above. $26.72
Current discount Discount to share price of $10.72
= -1 x ($10.72 - $26.72) / $26.72
59.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price Corcept Therapeutics is available for.
Intrinsic value
>50%
Share price is $10.72 vs Future cash flow value of $26.72
Current Discount Checks
For Corcept Therapeutics to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • Corcept Therapeutics's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • Corcept Therapeutics's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Corcept Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Corcept Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:CORT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $0.66
NasdaqCM:CORT Share Price ** NasdaqCM (2019-07-16) in USD $10.72
United States of America Pharmaceuticals Industry PE Ratio Median Figure of 29 Publicly-Listed Pharmaceuticals Companies 18.03x
United States of America Market PE Ratio Median Figure of 3,084 Publicly-Listed Companies 17.98x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Corcept Therapeutics.

NasdaqCM:CORT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CORT Share Price ÷ EPS (both in USD)

= 10.72 ÷ 0.66

16.22x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Corcept Therapeutics is good value based on earnings compared to the US Pharmaceuticals industry average.
  • Corcept Therapeutics is good value based on earnings compared to the United States of America market.
Price based on expected Growth
Does Corcept Therapeutics's expected growth come at a high price?
Raw Data
NasdaqCM:CORT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 16.22x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-13.1%per year
United States of America Pharmaceuticals Industry PEG Ratio Median Figure of 21 Publicly-Listed Pharmaceuticals Companies 1.8x
United States of America Market PEG Ratio Median Figure of 2,125 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

NasdaqCM:CORT PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 16.22x ÷ -13.1%

-1.24x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Corcept Therapeutics earnings are not expected to grow next year, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Corcept Therapeutics's assets?
Raw Data
NasdaqCM:CORT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $2.49
NasdaqCM:CORT Share Price * NasdaqCM (2019-07-16) in USD $10.72
United States of America Pharmaceuticals Industry PB Ratio Median Figure of 185 Publicly-Listed Pharmaceuticals Companies 3.07x
United States of America Market PB Ratio Median Figure of 5,240 Publicly-Listed Companies 1.81x
NasdaqCM:CORT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CORT Share Price ÷ Book Value per Share (both in USD)

= 10.72 ÷ 2.49

4.31x

* Primary Listing of Corcept Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Corcept Therapeutics is overvalued based on assets compared to the US Pharmaceuticals industry average.
X
Value checks
We assess Corcept Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Corcept Therapeutics has a total score of 4/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Corcept Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-13.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Corcept Therapeutics expected to grow at an attractive rate?
  • Corcept Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Corcept Therapeutics's earnings are expected to decrease over the next 1-3 years, this is below the United States of America market average.
  • Corcept Therapeutics's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:CORT Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:CORT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -13.1%
NasdaqCM:CORT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 4 Analysts 0%
United States of America Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 16.4%
United States of America Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 5.7%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 14.1%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:CORT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:CORT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 334 91 1
2022-12-31 218 7 1
2021-12-31 272 52 1
2020-12-31 339 127 4
2019-12-31 295 97 4
NasdaqCM:CORT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 258 105 76
2018-12-31 251 116 75
2018-09-30 238 119 152
2018-06-30 216 85 148
2018-03-31 189 86 142
2017-12-31 159 61 129
2017-09-30 130 41 35
2017-06-30 109 39 24
2017-03-31 93 25 13
2016-12-31 81 18 8
2016-09-30 72 18 5
2016-06-30 64 10 1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Corcept Therapeutics's earnings are expected to decrease over the next 1-3 years, this is not considered high growth.
  • Corcept Therapeutics's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:CORT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Corcept Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:CORT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.67 0.67 0.67 1.00
2022-12-31 0.05 0.05 0.05 1.00
2021-12-31 0.40 0.40 0.40 1.00
2020-12-31 1.02 1.23 0.86 4.00
2019-12-31 0.80 0.90 0.70 4.00
NasdaqCM:CORT Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 0.66
2018-12-31 0.65
2018-09-30 1.32
2018-06-30 1.29
2018-03-31 1.25
2017-12-31 1.14
2017-09-30 0.31
2017-06-30 0.22
2017-03-31 0.11
2016-12-31 0.07
2016-09-30 0.04
2016-06-30 0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Corcept Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Corcept Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Corcept Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Corcept Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Corcept Therapeutics's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Corcept Therapeutics has delivered over 20% year on year earnings growth in the past 5 years.
  • Corcept Therapeutics's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • Corcept Therapeutics's 1-year earnings growth is negative, it can't be compared to the US Pharmaceuticals industry average.
Earnings and Revenue History
Corcept Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Corcept Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:CORT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 258.42 76.23 87.24 78.44
2018-12-31 251.25 75.41 81.29 75.25
2018-09-30 237.70 151.73 76.52 70.08
2018-06-30 216.01 147.74 71.69 62.92
2018-03-31 189.26 142.19 65.82 50.25
2017-12-31 159.20 129.12 62.42 40.38
2017-09-30 129.73 35.39 57.38 33.23
2017-06-30 108.69 24.22 51.84 28.59
2017-03-31 92.86 12.55 49.85 26.39
2016-12-31 81.32 8.14 45.24 23.84
2016-09-30 72.48 4.50 42.34 21.45
2016-06-30 64.01 1.32 40.70 18.01
2016-03-31 56.25 -1.60 37.93 15.68
2015-12-31 50.29 -6.41 36.95 15.42
2015-09-30 44.33 -11.26 36.13 15.12
2015-06-30 38.35 -16.67 35.94 14.55
2015-03-31 32.25 -22.28 34.56 15.46
2014-12-31 26.55 -31.38 34.92 18.37
2014-09-30 21.65 -38.61 34.39 21.15
2014-06-30 17.00 -43.51 32.47 23.26
2014-03-31 13.05 -47.86 32.66 23.50
2013-12-31 10.36 -46.01 31.24 20.47
2013-09-30 7.62 -46.01 30.21 18.76
2013-06-30 6.04 -43.40 28.72 16.61
2013-03-31 5.02 -39.10 26.31 14.79
2012-12-31 3.31 -38.05 25.41 14.07
2012-09-30 1.93 -36.86 22.21 15.86

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Corcept Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
  • Corcept Therapeutics used its assets more efficiently than the US Pharmaceuticals industry average last year based on Return on Assets.
  • Corcept Therapeutics has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Corcept Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Corcept Therapeutics has a total score of 4/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Corcept Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Corcept Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Corcept Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Corcept Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Corcept Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Corcept Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Corcept Therapeutics Company Filings, last reported 3 months ago.

NasdaqCM:CORT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 285.76 0.00 186.91
2018-12-31 275.88 0.00 206.76
2018-09-30 259.55 0.00 195.19
2018-06-30 243.51 0.00 159.95
2018-03-31 215.23 0.00 125.36
2017-12-31 190.97 0.00 88.74
2017-09-30 86.30 0.00 75.16
2017-06-30 66.15 4.57 66.17
2017-03-31 49.58 10.11 52.77
2016-12-31 41.38 14.66 51.54
2016-09-30 31.25 18.73 47.87
2016-06-30 25.66 22.30 41.79
2016-03-31 20.17 25.04 40.74
2015-12-31 18.50 27.49 40.44
2015-09-30 13.48 29.64 36.45
2015-06-30 11.53 31.43 37.05
2015-03-31 10.57 32.78 37.95
2014-12-31 -3.39 33.89 24.25
2014-09-30 -1.32 34.65 26.78
2014-06-30 3.45 35.03 33.97
2014-03-31 9.37 35.11 43.62
2013-12-31 21.02 35.07 54.88
2013-09-30 30.77 34.64 63.18
2013-06-30 40.37 33.89 72.22
2013-03-31 51.00 32.80 81.46
2012-12-31 61.78 31.68 93.03
2012-09-30 71.65 30.58 101.63
  • Corcept Therapeutics has no debt.
  • Corcept Therapeutics has no debt compared to 5 years ago when it was 377.3%.
  • Corcept Therapeutics has no debt, it does not need to be covered by operating cash flow.
  • Corcept Therapeutics has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Corcept Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Corcept Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Corcept Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Corcept Therapeutics dividends. Estimated to be 0% next year.
If you bought $2,000 of Corcept Therapeutics shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Corcept Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Corcept Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:CORT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
United States of America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2017 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:CORT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Corcept Therapeutics has not reported any payouts.
  • Unable to verify if Corcept Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Corcept Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Corcept Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Corcept Therapeutics's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess Corcept Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Corcept Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Corcept Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Corcept Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Joseph Belanoff
COMPENSATION $6,314,617
AGE 62
TENURE AS CEO 20.5 years
CEO Bio

Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and has held various positions in the Department of Psychiatry and Behavioral Sciences at Stanford University since 1992. From 1997 to 2001, he served as Director of Psychopharmacology at the outpatient division of the Palo Alto Veterans Affairs Hospital. Dr. Belanoff has been a Director of Corcept Therapeutics Incorporated since 1999. He serves as Member of Advisory Board at Immusoft Corporation. He also has valuable expertise in business administration, drug discovery, clinical medicine and psychopharmacology. Dr. Belanoff received his B.A. from Amherst College and his M.D. from the Columbia University's College of Physicians & Surgeons.

CEO Compensation
  • Joseph's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
  • Joseph's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Corcept Therapeutics management team in years:

3.3
Average Tenure
57
Average Age
  • The tenure for the Corcept Therapeutics management team is about average.
Management Team

Joseph Belanoff

TITLE
Co-Founder
COMPENSATION
$6M
AGE
62
TENURE
20.5 yrs

Charlie Robb

TITLE
CFO & Secretary
COMPENSATION
$3M
AGE
56
TENURE
7.8 yrs

Sean Maduck

TITLE
Senior Vice President of Commercial
COMPENSATION
$3M
AGE
42
TENURE
3.3 yrs

Chris James

TITLE
Director of Investor Relations

Hazel Hunt

TITLE
Senior Vice President of Research
TENURE
2.3 yrs

Don Laferle

TITLE
Senior Vice President

Andreas Grauer

TITLE
Chief Medical Officer
AGE
58
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Corcept Therapeutics board of directors in years:

20.5
Average Tenure
65
Average Age
  • The average tenure for the Corcept Therapeutics board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Jim Wilson

TITLE
Chairman
COMPENSATION
$759K
AGE
75
TENURE
20.5 yrs

Joseph Belanoff

TITLE
Co-Founder
COMPENSATION
$6M
AGE
62
TENURE
20.5 yrs

Len Baker

TITLE
Director
COMPENSATION
$268K
AGE
76
TENURE
20.5 yrs

David Mahoney

TITLE
Director
COMPENSATION
$273K
AGE
65
TENURE
15 yrs

Dan Swisher

TITLE
Independent Director
COMPENSATION
$280K
AGE
56
TENURE
4.1 yrs

Charles Nemeroff

TITLE
Member of Scientific Advisory Board
AGE
69

Bruce McEwen

TITLE
Member of Scientific Advisory Board

K. Ranga Krishnan

TITLE
Member of Scientific Advisory Board
AGE
63

Ned Kalin

TITLE
Member of Scientific Advisory Board

Florian Holsboer

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
14. Feb 19 Buy George Baker Individual 12. Feb 19 12. Feb 19 100,000 $11.39 $1,138,710
26. Nov 18 Buy George Baker Individual 21. Nov 18 21. Nov 18 100,000 $12.73 $1,272,550
14. Nov 18 Buy George Baker Individual 09. Nov 18 13. Nov 18 200,000 $13.00 $2,589,230
22. Aug 18 Buy George Baker Individual 20. Aug 18 20. Aug 18 35,681 $12.92 $461,095
20. Aug 18 Buy George Baker Individual 16. Aug 18 17. Aug 18 105,792 $12.80 $1,322,877
16. Aug 18 Buy George Baker Individual 14. Aug 18 15. Aug 18 179,686 $12.49 $2,241,967
X
Management checks
We assess Corcept Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Corcept Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Should Investors Know About Corcept Therapeutics Incorporated's (NASDAQ:CORT) Future?

Below is a brief commentary around Corcept Therapeutics's earnings outlook going forward, which may give you a sense of market sentiment for the company. … View our latest analysis for Corcept Therapeutics How is Corcept Therapeutics going to perform in the near future? … NasdaqCM:CORT Past and Future Earnings, July 8th 2019 By 2022, CORT's earnings should reach US$40m, from current levels of US$75m, resulting in an annual growth rate of -13%.

Simply Wall St -

Should You Consider Corcept Therapeutics Incorporated (NASDAQ:CORT)?

NasdaqCM:CORT Income Statement, June 25th 2019 CORT is currently trading below its true value, which means the market is undervaluing the company's expected cash flow going forward. … According to my intrinsic value of the stock, which is driven by analyst consensus forecast of CORT's earnings, investors now have the opportunity to buy into the stock to reap capital gains. … Dividend Income vs Capital Gains: Does CORT return gains to shareholders through reinvesting in itself and growing earnings, or redistribute a decent portion of earnings as dividends?

Simply Wall St -

Is Corcept Therapeutics Incorporated (NASDAQ:CORT) Excessively Paying Its CEO?

View our latest analysis for Corcept Therapeutics How Does Joseph Belanoff's Compensation Compare With Similar Sized Companies? … Thus we can conclude that Joseph Belanoff receives more in total compensation than the median of a group of companies in the same market, and of similar size to Corcept Therapeutics Incorporated. … We compared the total CEO remuneration paid by Corcept Therapeutics Incorporated, and compared it to remuneration at a group of similar sized companies.

Simply Wall St -

Could The Corcept Therapeutics Incorporated (NASDAQ:CORT) Ownership Structure Tell Us Something Useful?

A look at the shareholders of Corcept Therapeutics Incorporated (NASDAQ:CORT) can tell us which group is most powerful. … Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. … institutions are noticeable on the share registry.

Simply Wall St -

Why Corcept Therapeutics Incorporated (NASDAQ:CORT) Looks Like A Quality Company

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it is important. … Our data shows Corcept Therapeutics has a return on equity of 27% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Is Corcept Therapeutics Incorporated's (NASDAQ:CORT) P/E Ratio Really That Good?

We'll look at Corcept Therapeutics Incorporated's (NASDAQ:CORT) P/E ratio and reflect on what it tells us about the company's share price. … Corcept Therapeutics has a P/E ratio of 17.96, based on the last twelve months. … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St -

Corcept Therapeutics (NASDAQ:CORT) Shareholders Have Enjoyed An Impressive 195% Share Price Gain

Corcept Therapeutics Incorporated (NASDAQ:CORT) shareholders might be concerned after seeing the share price drop 21% in the last quarter. … In his essay The Superinvestors of Graham-and-Doddsville Warren Buffett described how share prices do not always rationally reflect the value of a business. … During the five years of share price growth, Corcept Therapeutics moved from a loss to profitability.

Simply Wall St -

Why Corcept Therapeutics Incorporated (NASDAQ:CORT) Is An Attractive Investment To Consider

In the case of Corcept Therapeutics Incorporated (NASDAQ:CORT), there's. … Below is a brief commentary on these key aspects … If you're interested in understanding beyond my broad commentary,

Simply Wall St -

Is There An Opportunity With Corcept Therapeutics Incorporated's (NASDAQ:CORT) 48.21% Undervaluation?

by projecting its future cash flows and then discounting them to today's value. … Discounted Cash Flows (DCF) … If you want to learn more about discounted cash flow, the basis for my calcs can be read in detail in the Simply Wall St analysis model.

Simply Wall St -

Does Corcept Therapeutics Incorporated's (NASDAQ:CORT) CEO Pay Reflect Performance?

Joseph Belanoff became the CEO of Corcept Therapeutics Incorporated (NASDAQ:CORT) in 1999. … This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Joseph Belanoff's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Company Info

Description

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant that is in Phase III clinical trial to treat patients with Cushing’s syndrome; and Abraxane in combination with relacorilant, which is in Phase II clinical trial to treat metastatic ovarian cancer, as well as in Phase I/II clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator CORT125281 combined with Xtandi that is in open label Phase I/II trial to treat patients with metastatic castration-resistant prostate cancer; CORT118335 selective cortisol modulator for the treatment of antipsychotic-induced weight gain and non-alcoholic steatotic hepatitis; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Details
Name: Corcept Therapeutics Incorporated
CORT
Exchange: NasdaqCM
Founded: 1998
$1,231,285,349
114,858,708
Website: http://www.corcept.com
Address: Corcept Therapeutics Incorporated
149 Commonwealth Drive,
Menlo Park,
California, 94025,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CORT Common Stock Nasdaq Capital Market US USD 14. Apr 2004
DB HTD Common Stock Deutsche Boerse AG DE EUR 14. Apr 2004
LSE 0I3Q Common Stock London Stock Exchange GB USD 14. Apr 2004
Number of employees
Current staff
Staff numbers
166
Corcept Therapeutics employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/16 23:53
End of day share price update: 2019/07/16 00:00
Last estimates confirmation: 2019/06/11
Last earnings filing: 2019/05/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.